Safety and efficacy of IFN/RBV-free DAA-based regimens in HCV-recurrence after Orthotopic Liver Transplantation
S Beinhardt, R Al-Zoairy, K Kozbial, R Stern, A Stättermayer, A Maieron, R Stauber, M Strasser, H Zoller, I Graziadei, M Trauner, P Ferenci, H Hofer · Zeitschrift für Gastroenterologie · 2016 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background & Aim: Interferon-free DAA combinations allow an effective treatment of HCV recurrence after orthotopic liver transplantation (OLT), but the role of ribavirin (RBV) in the post transplant setting is still under debate. So far published data gained from IFN/RBV-free DAA-based regimens are sparse. We thus aimed to analyze safety and efficacy of IFN/RBV-free DAA-based regimens in HCV-recurrence after OLT. Patients & Methods: 62 patients (male: 50/81%; age: 61 ± 8.5 years [mean ± SD]; GT1: 48/77%, GT3: 9/15%, GT4: 5/8%; experienced: 43/69%, cirrhotic: 34/55% [decompensated: 7/11%]; fulminant cholestatic h…
